Prevalence of mismatch-repair deficiency in rectal adenocarcinomas
DJ Papke Jr, MB Yurgelun, AE Noffsinger… - … England Journal of …, 2022 - Mass Medical Soc
DJ Papke Jr, MB Yurgelun, AE Noffsinger, KO Turner, RM Genta, M Redston
New England Journal of Medicine, 2022•Mass Medical Soc… Cercek and colleagues (June 23 issue) 1 report the findings of a case series of 12
patients with locally advanced mismatch repair (MMR)–deficient rectal adenocarcinomas
who had complete responses to neoadjuvant monotherapy with dostarlimab, an anti–programmed
death 1 antibody. The authors estimated (partly on the basis of data from tertiary referral
centers) that the … Overall, we found that 2.7% of rectal adenocarcinomas were MMR
deficient. The relatively older median age at the time of presentation with MMR-deficient …
patients with locally advanced mismatch repair (MMR)–deficient rectal adenocarcinomas
who had complete responses to neoadjuvant monotherapy with dostarlimab, an anti–programmed
death 1 antibody. The authors estimated (partly on the basis of data from tertiary referral
centers) that the … Overall, we found that 2.7% of rectal adenocarcinomas were MMR
deficient. The relatively older median age at the time of presentation with MMR-deficient …
Mismatch-Repair Deficiency in Rectal Cancer
Immunohistochemical analysis of 5547 rectal adenocarcinoma biopsy specimens showed the presence of mismatch-repair deficiency in 2.7% of rectal tumors and in 13.4% of colorectal adenocarcinomas.
The New England Journal Of Medicine以上显示的是最相近的搜索结果。 查看全部搜索结果